Few Signs Of An IPO Slowdown Despite US Biotech Stock Slump

Biotech stock valuations wavered in October with the average IPO return in the US nearing negative territory, but observers say there is still a healthy market for new biopharma offerings in 2018 and into next year.

IV1812_Business-IPO-Slowdown_1200.jpg
• Source: Shutterstock

There is no question that the market for biopharmaceutical company initial public offerings in the US is booming, but it remains to be seen if a major drop in biotechnology stock values in October will slow the momentum, especially since the average IPO return is approaching zero.

Of the 61 biopharma firms that launched IPOs in 2018 through the end of October, 33 provided negative returns and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.